Leverage the Intersection of AI & Computational Approaches for Multi-Objective Optimization of Affinity, Thermostability & Immunogenicity to Design Developability-Optimized Biologics With Derisked CMC
AI/ML and computational approaches for biologics design and optimization continued to demonstrate their transformative impact across the industry throughout the year. Milestones such as Latent Labs’ launch to develop biologics using advanced AI models, Eli Lilly’s TuneLab partnerships with BigHat Bio and Chai Discovery, and Bayer’s collaboration with Cradle on AI-enabled antibody discovery reinforced the role of AI as a critical accelerant in re-architecting biologics workflows and streamlining the path from discovery through lead candidate optimization.
Against this backdrop, the re-imagined CDD & AI for Biologics Summit brought together the industry's leading innovators to share applied, experimentally validated use cases and practical strategies for advancing biologics discovery. Across the event, attendees explored the convergence of computational drug design and AI through sessions covering de novo protein design, property prediction, multi-objective optimization, molecular dynamics mapping, and developability assessment.
The summit united techbio pioneers and biotech innovators including Insilico Medicine, insitro, 3T Biosciences, and AI Proteins, alongside leading pharmaceutical organizations such as Eli Lilly, Merck, AstraZeneca, AbbVie, and Amgen. Through presentations, case studies, and discussions, computational biologists, data scientists, developability specialists, and AI/ML leaders gained valuable insights into how emerging AI-driven approaches can be operationalized alongside both established and novel computational methodologies.
Participants left the event with actionable learnings, new industry connections, and a clearer understanding of how to advance AI-enabled biologics through discovery pipelines while mitigating development and CMC risk. The summit successfully fostered collaboration across the biologics ecosystem, equipping attendees with the knowledge and partnerships needed to accelerate innovation and move promising therapeutics closer to delivering value for patients.
The conference has a uniquely intimate and collegial atmosphere where participants are very open and approachable. The discussions will be vibrant, innovative, and genuinely collaborative, making it an inspiring environment to exchange ideas and build meaningful connections
Gábor Oroszlán, Senior Manager, Miniprotein Platform Lead, VRG Therapeutics, 2026 Speaker
This is a great opportunity to connect with industry and academic experts on important topics in computational drug discovery for biologics. The focused agenda and smaller setting will allow for more in-depth discussions and a chance to gain valuable insights
Nandhini Rajagopal, Principal Scientist, Computational Biophysics, Genentech, 2026 Speaker
I look forward to gaining exposure to practical strategies for combining high-throughput experimentation with ML, and focusing on real-world implementation, rather than theory alone
Noam Katz, Director, ML & ISR Site Lead, insitro, 2026 Speaker
Having attended before, I'm excited to continue to gain fresh, actionable insights and valuable industry connections that refine our DMTA cycles and improve predictability in candidate selection. It is great to hear real-world case studies and practical validation strategies for AI/ML and de novo approaches that we can apply immediately to our biologics discovery
Lindsay Hammack, Associate Principal Scientist, Merck, 2026 Speaker
Why This Summit is the ‘Best Fit’ For You
Dive into the 2026 Program to Find:
- 20+ World-Class Computational & AI/ML-Guided Biologics Speakers with Expertise Spanning Discovery, Design & Optimization
- 8+ Hours of Unmatched Networking & Strategic Partnering Opportunities
- 2 Days of Exclusive Content Providing Best-in-Class AI/ML Use Cases & Insights
- 2 In-Conference Deep Dive Workshops Offering Perspectives on Data Readiness & Lab Automation for AI-Enabled Biologic Therapeutics Design
- A Focused, Industry-Lead Community of Top Techbio, Pharma & Biotech Organizations
2026 Speaker Faculty
2026 Official Partners
Who We Connected With
Discover the 2026 Agenda
Catch the latest industry breakthroughs, emerging trends and exclusive insights by participating in our dynamic roundtables and panel discussions.
Prioritize Partnering With Us
As the field rapidly expands and matures, position yourself alongside leading solution providers to ensure your brand stands out as a premier choice, amid growing competition.
Join Your Community
Immerse yourself in critical conversations with like-minded experts spanning all stages of development, from in silico to de novo biologics design and developability optimization, and build invaluable connections.